- Home
- EU vs PLRX Comparison
EU vs PLRX Comparison
Compare EU & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EU
- PLRX
- Stock Information
- Founded
- EU 2009
- PLRX 2015
- Country
- EU United States
- PLRX United States
- Employees
- EU N/A
- PLRX N/A
- Industry
- EU Other Metals and Minerals
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- EU Basic Materials
- PLRX Health Care
- Exchange
- EU Nasdaq
- PLRX Nasdaq
- Market Cap
- EU 445.3M
- PLRX 89.0M
- IPO Year
- EU N/A
- PLRX 2020
- Fundamental
- Price
- EU $2.58
- PLRX $1.46
- Analyst Decision
- EU Strong Buy
- PLRX Hold
- Analyst Count
- EU 1
- PLRX 10
- Target Price
- EU $4.00
- PLRX $3.93
- AVG Volume (30 Days)
- EU 5.2M
- PLRX 692.5K
- Earning Date
- EU 11-13-2025
- PLRX 11-06-2025
- Dividend Yield
- EU N/A
- PLRX N/A
- EPS Growth
- EU N/A
- PLRX N/A
- EPS
- EU N/A
- PLRX N/A
- Revenue
- EU $44,524,000.00
- PLRX N/A
- Revenue This Year
- EU $33.35
- PLRX N/A
- Revenue Next Year
- EU $112.45
- PLRX N/A
- P/E Ratio
- EU N/A
- PLRX N/A
- Revenue Growth
- EU N/A
- PLRX N/A
- 52 Week Low
- EU $1.01
- PLRX $1.10
- 52 Week High
- EU $4.44
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- EU 56.05
- PLRX 40.86
- Support Level
- EU $2.21
- PLRX $1.66
- Resistance Level
- EU $2.37
- PLRX $1.85
- Average True Range (ATR)
- EU 0.13
- PLRX 0.12
- MACD
- EU 0.04
- PLRX -0.03
- Stochastic Oscillator
- EU 87.06
- PLRX 2.27
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.